Insider Buying: CorMedix Inc. (CRMD) Director Buys 42,000 Shares of Stock
CorMedix Inc. (NYSEAMERICAN:CRMD) Director Janet Dillione bought 42,000 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average price of $1.67 per share, with a total value of $70,140.00. Following the purchase, the director now owns 180,909 shares of the company’s stock, valued at $302,118.03. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
NYSEAMERICAN CRMD traded down $0.05 on Wednesday, reaching $1.53. The stock had a trading volume of 2,957,801 shares, compared to its average volume of 3,021,363. CorMedix Inc. has a 12-month low of $0.17 and a 12-month high of $2.74.
Several equities research analysts recently weighed in on CRMD shares. Roth Capital started coverage on CorMedix in a research note on Thursday, December 6th. They set a “buy” rating and a $6.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $3.50 price objective on shares of CorMedix in a research note on Wednesday, December 12th. Finally, Zacks Investment Research cut CorMedix from a “hold” rating to a “sell” rating in a research note on Friday, December 14th.
ILLEGAL ACTIVITY WARNING: “Insider Buying: CorMedix Inc. (CRMD) Director Buys 42,000 Shares of Stock” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/insider-buying-cormedix-inc-crmd-director-buys-42000-shares-of-stock/2905044.html.
CorMedix Company Profile
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Further Reading: Understanding each part of a balance sheet
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.